以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - aliskiren 300 mg - film coated tablets - aliskiren - treatment of essential hypertension.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - fluvastatin as sodium 20 mg - capsules - fluvastatin - reduction of elevated levels of total cholesterol, ldl cholesterol, apolipoprotein b and triglycerides and increase of hdl cholesterol in patients with primary hypercholesterolemia and primary mixed dyslipidemia (fredrickson types iia and iib) in whom dietary measures have proved insufficiently effective.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - fluvastatin as sodium 40 mg - capsules - fluvastatin - reduction of elevated levels of total cholesterol, ldl cholesterol, apolipoprotein b and triglycerides and increase of hdl cholesterol in patients with primary hypercholesterolemia and primary mixed dyslipidemia (fredrickson types iia and iib) in whom dietary measures have proved insufficiently effective.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - potassium chloride 600 mg - tablets slow release - potassium chloride - treatment and prevention of hypokalaemia.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - phentolamine mesylate 10 mg/ml - solution for injection - phentolamine - 1. management of hypertensive crises which may occur in patients with phaeochromocytoma e.g. during pre-operative preparation and surgical intervention. 2. diagnosis of phaeochromocytoma by the regitine test if other specific tests are not available.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - tetracosactide hexaacetate 1 mg/ml - suspension for injection - tetracosactide - collagen diseases, neurological diseases, chronic skin disorders.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - calcitonin salmon 2200 iu/ml - solution - calcitonin (salmon synthetic) - bone pain associated with osteolysis due to malignancies. paget's disease of bone only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. neurodystrophic disorders.

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - diclofenac sodium 50 mg - suppositories - diclofenac - anti-rheumatic, anti-inflammatory, analgesic

以色列 - 希伯来文 - Ministry of Health

novartis pharma services ag - entacapone 200 mg - film coated tablets - entacapone - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.